Dragon Life Science Holdings Group, Inc.
NOHO · OTC
8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.16 |
| FCF Yield | -2.19% | -249.70% | 0.00% | 0.00% |
| EV / EBITDA | 36.90 | -309.20 | -325.98 | -133.09 |
| Quality | ||||
| ROIC | 35.25% | 0.73% | 1.01% | 33.25% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.07 | 0.03 | – | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1,232.70% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -308.80 | -288.62 | -117.84 |
| Interest Coverage | -4.17 | -0.03 | -0.01 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |